Novaliq Overview

  • Founded
  • 2007
  • Status
  • Private
  • Employees
  • 33
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $53M
Latest Deal Amount
  • Investors
  • 1

Novaliq General Information


Operator of a drug delivery company designed to develop innovative pharmaceutical formulations. The company's drugs focus on the development and commercialization of ocular therapeutics for dry eye disease (DED) based on EyeSol, thereby enabling ophthalmologists with a suitable option for eye treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Primary Office
  • Im Neuenheimer Feld 515
  • 69120 Heidelberg
  • Germany
+49 06221 000000

Novaliq Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novaliq Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 11-Oct-2018 $53M 00000 Completed Clinical Trials - Phase 2
5. Later Stage VC 11-Oct-2018 00000 00000 Completed Generating Revenue
4. Later Stage VC 11-Apr-2013 0000 000.00 Completed Pre-Clinical Trials
3. Later Stage VC 02-May-2012 00.000 000.00 Completed Pre-Clinical Trials
2. Later Stage VC 15-Jul-2011 $3.29M $12.5M Completed Pre-Clinical Trials
1. Early Stage VC 01-Jan-2007 $9.2M $9.2M Completed Generating Revenue
To view Novaliq’s complete valuation and funding history, request access »

Novaliq Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Operator of a drug delivery company designed to develop innovative pharmaceutical formulations. The company's drugs focu
Drug Discovery
Heidelberg, Germany
33 As of 2020
0000000000 0 00000


smod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000 000000000
Malvern, PA
00 As of 0000
000000000 000.00


nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
Allschwil, Switzerland
0000 As of 0000
00.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novaliq Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ocugen Corporation Malvern, PA 00 000.00 000000000 000.00
00000000 000000000 Formerly VC-backed Allschwil, Switzerland 0000 00000 000000&0 00000
You’re viewing 2 of 2 competitors. Get the full list »

Novaliq Executive Team (13)

Name Title Board Seat Contact Info
Christian Roesky Ph.D Chief Executive Officer & Managing Director
Oliver Schlüter Ph.D Chief Financial Officer & Managing Director
Frank Löscher Ph.D Chief Technology Officer
Jörg Haißer Director of Analytics / Head of Quality Control
Karen Pasig Director, Finance & Accounting
You’re viewing 5 of 13 executive team members. Get the full list »

Novaliq Board Members (7)

Name Representing Role Since
Berthold Wipfler Self Supervisory Board Member 000 0000
Friedrich Von Bohlen Ph.D dievini Chairman of the Supervisory board 000 0000
Mathias Hothum Ph.D dievini Supervisory Board Member 000 0000
Thomas Kaercher Self Supervisory Board Member 000 0000
Volker Geuder Self Supervisory Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Novaliq Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novaliq Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
dievini Venture Capital Minority 000 0000 000000 0
To view Novaliq’s complete investors history, request access »

Novaliq Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 10-Oct-2018 00000 0000000 Pharmaceuticals 000000000 000000 00.0
To view Novaliq’s complete investments history, request access »